EYESIS Intense Pulsed Light Meibomian Gland Dysfunction Therapeutic Device – Medixine Featured on Artery New Product Showcase Episode 114

Dry Eye as a Chronic Ocular Surface Disease: In 2017, DEWS II defined dry eye as "a multifactorial disease of the ocular surface characterized by a loss of tear film homeostasis, accompanied by ocular symptoms, whose pathophysiology includes tear film instability, hyperosmolarity of the tear film, ocular surface inflammation and damage, and neurosensory abnormalities." In the dry eye guidelines, the treatment for dry eye is divided into physical therapy and medication. Currently, commonly used medications in clinical practice include artificial tears and cyclosporine, which can alleviate dry eye symptoms and treat inflammation. However, medication alone is often insufficient to achieve effective treatment outcomes. Therefore, to effectively alleviate and treat dry eye syndrome, a combination of drugs and medical devices is frequently adopted in clinical practice, with some practitioners also choosing to innovate and focus on advancements within the ophthalmic device field.

MDC EYESIS^®️The Meibomian Gland Dysfunction Treatment Device with Light Pulses adopts the brand-new fourth-generation MOPT technology (Multiple Optimal Plus Technology, Multiple Optimized Pulsed Light Technology), which is highly recommended by the National Health Technology Promotion and Application Information Service Platform for clinical treatment of MGD and related dry eye conditions. This treatment device has been introduced in over 800 hospitals and relevant institutions.

This therapy device adopts the fourth-generation IPL technology, incorporating more pulses of varying energy. Its thermal conductivity surpasses similar products, and it can better control the energy density of IPL and thermal relaxation time, enhancing both comfort and treatment effectiveness simultaneously. The unique water-cooling technology reduces the temperature of the crystal treatment head to freezing point, while controlling the excitation voltage at 12V to improve safety protection for both patients and doctors.

On November 20th (Wednesday) at 19:30, the 114th edition of VCBeat's New Product Review is inviting...MDCFounder/CEO of MDC Gao Chengsen, Director/Strategic Advisor of Make Dreams Connect Feng TaoTwo guests present the product promotion of MDC.

Independent Intellectual Property Rights: The Only 10-Pulse MOPT Technology

EYESIS^®Fourth-Generation Optical Pulse (MOPT) Technology Meibomian Gland Dysfunction (MGD) Treatment System

Indications:Treatment of Meibomian Gland Dysfunction (MGD) caused by inflammation, abnormal blood vessel growth, and demodex mites.

Wavelength: 580 nm—1200 nm 

Commonly Used Energy:5J/cm2 —15J/cm2

Treatment Head Cooling:Active cooling reduces skin surface temperature and prevents skin burns;

Comfort:Mild and less irritating;

Number of pulses in pulse cluster ≥ 10

1. Rapidly seal new capillaries, reduce the release of inflammatory factors, suppress ocular hyperemia, and alleviate ocular inflammatory responses.

2. Instantly soften and liquefy meibum within 1-2 seconds, clear the meibomian gland secretions for normal discharge, ensure unobstructed meibomian gland orifices, and retain tear fluid without pressure.

3. Rapidly eliminate Demodex mites, parasites, and bacteria, block the inflammatory cascade reaction, and achieve the therapeutic effect for Demodex blepharitis.

4. Photobiomodulation (PBM) can promote the proliferation of acinar basal cells, reduce reactive oxygen species and apoptosis, and restore the biological function of meibomian glands. Meanwhile, it stimulates collagen fiber regeneration and rejuvenates ocular tissues.

Scan the QR code on the poster to add the assistant and schedule a live broadcast.

Gao Chengsen

Founder/CEO of MDC

● Hebei Medical University, Clinical Medicine Major;

● MBA from Guanghua School of Management, Peking University;

●3 years of experience as a surgeon;

● More than 20 years of work experience in multinational corporations, publicly listed companies, and self-founded startups within the pharmaceuticals field; founded and held core positions such as sales and operations management in pharmaceutical and medical device companies.

● In 2008, MDC (Beijing) Pharmaceutical Technology Co., Ltd. was established, collaborating with Sinopharm Group and Japan's Nitto Denko Corporation to promote transdermal absorption of new drugs. In 2014, the full equity of the company was transferred, while retaining personal trademark rights for MDC in the medical device industry.

● In 2009, MDC was founded to start the research, development, production, and sales of medical devices;

● MDC has been focusing on the research and development of ophthalmic dry eye products since 2014. In 2019, its first "Ophthalmic Intense Pulsed Light Dry Eye Treatment Device" specifically developed for dry eye treatment was approved for marketing by the National Medical Products Administration (NMPA).

Feng Tao

MDC Medical Company Director / Strategic Advisor

● Bachelor of Accounting from Central University of Finance and Economics;

● MBA from Guanghua School of Management, Peking University;

● Formerly served in the Financial Department of the Ministry of Foreign Affairs and at Chinese embassies abroad;

● Co-founder of Yutao Capital;

● Formerly served as Vice President and CFO of NavInfo (002405.SZ);

● Formerly served as Executive Director and CFO of Tiandi Map Holdings (00402.HK), Chief Accountant of AVIC Joy Air Holdings, Vice General Manager of Harvest Technology Investment, etc.;

● Since 2004, he has been engaged in investment and enterprise management, with rich experience in enterprise management and cross-border investment and mergers & acquisitions, as well as IPO listings.

MDC Medical, founded in 2009, is a high-tech enterprise dedicated to the research, development, production, and sales of new technology products in the ophthalmic medical field. Since its establishment, MDC has insisted on introducing top-tier high-tech talents to build an efficient and innovative R&D team, successfully developing various medical products with international competitiveness. Currently, the company mainly focuses on the layout of dry eye diagnosis and treatment products, having developed and launched devices such as the Dry Eye Comprehensive Examination Instrument, Intense Pulsed Light Dry Eye Treatment Device, and Dry Eye Constant Temperature Fumigation Therapy Device. All three products have been included in the key promotion list of new technologies by China's National Health Commission New Technology Promotion Platform. In the future, MDC Medical will continue to expand into new research directions, develop advanced medical technologies, and provide society with better products and higher quality services.

"VCBeat New Product Review" is a live broadcast column that supports the release of innovative products by medical enterprises. The column's mission is: to assist in the milestone release of every medical innovation product. If your company has plans to release innovative medical products or significant milestones and wishes to participate in the VCBeat New Product Review, please contact the assistant for consultation.

Scan the QR code below to contact the assistant for live broadcast reservation (if already added, please ask the assistant directly).

Scan the QR code below to download the VCBeat app and register to watch the live stream.

Contact the assistant to send the live broadcast screenshot, participate in the lucky draw for a chance to win 【15-day trial membership of VBInsight】.